An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
SOTIO-BOXR1030Phase I/IIOPEN TO ACCRUAL *
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors